Should patients with hepatitis C genotype 2/3 infection who are slow responders to pegylated interferon/ribavirin have treatment duration extended?

Hepatology. 2015 Aug;62(2):660-1. doi: 10.1002/hep.27601. Epub 2015 Jun 12.

Authors

Carla Silva¹, Elizabeth Ianna¹, Tracey Jones¹, Joshua S Davis²

Affiliations

¹ Department of Gastroenterology, John Hunter Hospital, New Lambton, New South Wales, Australia.
² Global and Tropical Health Division, Menzies School of Health Research, Darwin, NT, Australia; and Department of Infectious Diseases, John Hunter Hospital, New Lambton Heights NSW, Australia.

PMID: 25380552
DOI: 10.1002/hep.27601

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Case-Control Studies
Drug Administration Schedule
Drug Therapy, Combination
Female
Genotype
Hepatitis C / drug therapy*
Hepatitis C / genetics*
Humans
Interferon-alpha / therapeutic use*
Male
Middle Aged
Polyethylene Glycols / therapeutic use*
Prognosis
Recombinant Proteins / therapeutic use
Retrospective Studies
Ribavirin / therapeutic use*
Risk Assessment
Severity of Illness Index
Time Factors
Treatment Outcome
Viral Load / drug effects*

Substances

Interferon-alpha
Recombinant Proteins
Polyethylene Glycols
Ribavirin
peginterferon alfa-2a